Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Shares Gap Up – Here’s Why

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) gapped up prior to trading on Tuesday . The stock had previously closed at $37.00, but opened at $39.8701. Swedish Orphan Biovitrum shares last traded at $39.8701, with a volume of 100 shares changing hands.

Analysts Set New Price Targets

A number of brokerages have recently commented on BIOVF. Danske downgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a research note on Thursday, February 19th. Barclays reissued an “overweight” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, February 24th. Finally, BNP Paribas Exane raised Swedish Orphan Biovitrum to an “outperform” rating in a research report on Tuesday, February 10th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy”.

Swedish Orphan Biovitrum Stock Down 3.5%

The company has a debt-to-equity ratio of 0.14, a current ratio of 0.90 and a quick ratio of 0.59. The stock has a market capitalization of $14.19 billion, a price-to-earnings ratio of 306.72 and a beta of 0.36. The firm’s fifty day moving average is $38.64 and its 200-day moving average is $35.59.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last issued its earnings results on Thursday, February 5th. The company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The business had revenue of $846.23 million for the quarter, compared to analyst estimates of $879.40 million. Swedish Orphan Biovitrum had a net margin of 1.43% and a return on equity of 15.74%.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.